Nautilus Biotechnology, Inc. NAUT
Updated: 11 Aug 2026
No signal published yet
We already track Nautilus Biotechnology and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Nautilus Biotechnology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Nautilus Biotechnology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 28, 2026, the company reported its second-quarter 2026 financial results, recognizing $0.2 million in revenue and holding $129.2 million in cash and investments. Nautilus also announced a strategic shift of R&D resources toward proteoform applications alongside an updated commercial roadmap for its Voyager platform.
What Firelda Watch includes for Nautilus Biotechnology, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Nautilus Biotechnology, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Nautilus Biotechnology free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more